Hervé Petite

Dr. Hervé Petite

Laboratory of Osteoarticular Biology, Bioengineering and Bioimaging, University of Paris cité, Paris, France
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2010 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MDM. Deschepper
M. Deschepper
KOK. Oudina
K. Oudina
BDBertrand David
Bertrand David
VMV. Myrtil
V. Myrtil
CCC. Collet
C. Collet
Hervé PetiteHervé Petite
Hervé Petite
Use of mesenchymal stem cells (MSCs) has emerged as a potential new treatment for various diseases but has generated marginally successful results. A consistent finding of most studies is massive death of transplanted cells. The present study examined the respective roles of glucose and continuous severe hypoxia on MSC viability and function with respect to bone tissue engineering. We hereby demonstrate for the first time that MSCs survive exposure to long‐term (12 days), severe (pO2 < 1.5 mmHg) hypoxia, provided glucose is available. To this end, an in vitro model that mimics the hypoxic environment and cell‐driven metabolic changes encountered by grafted sheep cells was established. In this model, the hallmarks of hypoxia (low pO2, hypoxia inducible factor‐1α expression and anaerobic metabolism) were present. When conditions switched from hypoxic (low pO2) to ischemic (low pO2 and glucose depletion), MSCs exhibited shrinking, decreased cell viability and ATP content due to complete exhaustion of glucose at day 6; these results provided evidence that ischemia led to the observed massive cell death. Moreover, MSCs exposed to severe, continuous hypoxia, but without any glucose shortage, remained viable and maintained both their in vitro proliferative ability after simulation with blood reperfusion at day 12 and their in vivo osteogenic ability. These findings challenge the traditional view according to which severe hypoxia per se is responsible for the massive MSC death observed upon transplantation of these cells and provide evidence that MSCs are able to withstand exposure to severe, continuous hypoxia provided that a glucose supply is available.

9 July 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
RLRebecca Landon
Rebecca Landon
VGVirginie Gueguen
Virginie Gueguen
Hervé PetiteHervé Petite
Hervé Petite
Didier LetourneurDidier Letourneur
Didier Letourneur
Graciela Pavon-DjavidGraciela Pavon-Djavid
Graciela Pavon-Djavid
FAFani Anagnostou
Fani Anagnostou
Oxidative stress (OS) plays a pivotal role in diabetes mellitus (DM) onset, progression, and chronic complications. Hyperglycemia-induced reactive oxygen species (ROS) have been shown to reduce insulin secretion from pancreatic β-cells, to impair insulin sensitivity and signaling in insulin-responsive tissues, and to alter endothelial cells function in both type 1 and type 2 DM. As a powerful antioxidant without side effects, astaxanthin (ASX), a xanthophyll carotenoid, has been suggested to contribute to the prevention and treatment of DM-associated pathologies. ASX reduces inflammation, OS, and apoptosis by regulating different OS pathways though the exact mechanism remains elusive. Based on several studies conducted on type 1 and type 2 DM animal models, orally or parenterally administrated ASX improves insulin resistance and insulin secretion; reduces hyperglycemia; and exerts protective effects against retinopathy, nephropathy, and neuropathy. However, more experimental support is needed to define conditions for its use. Moreover, its efficacy in diabetic patients is poorly explored. In the present review, we aimed to identify the up-to-date biological effects and underlying mechanisms of ASX on the ROS-induced DM-associated metabolic disorders and subsequent complications. The development of an in-depth research to better understand the biological mechanisms involved and to identify the most effective ASX dosage and route of administration is deemed necessary.

9 January 2018 in Stem Cells
Verified
Journal Article
Closed access
PDF file
AMAdrien Moya
Adrien Moya
JPJoseph Paquet
Joseph Paquet
MDMickael Deschepper
Mickael Deschepper
NLNathanael LAROCHETTE
Nathanael LAROCHETTE
KOKarim Oudina
Karim Oudina
Hervé PetiteHervé Petite
Hervé Petite

1 June 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
BCBaptiste Charbonnier
Baptiste Charbonnier
MMMathieu Manassero
Mathieu Manassero
MBMarianne Bourguignon
Marianne Bourguignon
ADAdeline Decambron
Adeline Decambron
HEHanane El-Hafci
Hanane El-Hafci
EPEsther Potier
Esther Potier

25 February 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
MDMickael Deschepper
Mickael Deschepper
MMMathieu Manassero
Mathieu Manassero
KOKarim Oudina
Karim Oudina
JPJoseph Paquet
Joseph Paquet
LMLaurent-Emmanuel Monfoulet
Laurent-Emmanuel Monfoulet
Hervé PetiteHervé Petite
Hervé Petite
A major limitation in the development of cellular therapies using human mesenchymal stem cells (hMSCs) is cell survival post-transplantation. In this study, we challenged the current paradigm of hMSC survival, which assigned a pivotal role to oxygen, by testing the hypothesis that exogenous glucose may be key to hMSC survival. We demonstrated that hMSCs could endure sustained near-anoxia conditions only in the presence of glucose. In this in vitro cell model, the protein expressions of Hif-1α and angiogenic factors were upregulated by the presence of glucose. Ectopically implanted tissue constructs supplemented with glucose exhibited four- to fivefold higher viability and were more vascularized compared to those without glucose at day 14. These findings provided the first direct in vitro and in vivo demonstration of the proangiogenic and prosurvival functions of glucose in hMSC upon transplantation and identified glucose as an essential component of the ideal scaffold for transplanting stem cells.

22 June 2011 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
CNChristophe Nich
Christophe Nich
JLJean Langlois
Jean Langlois
AMArnaud Marchadier
Arnaud Marchadier
CVCatherine Vidal
Catherine Vidal
MCMartine Cohen-Solal
Martine Cohen-Solal
MHMoussa Hamadouche
Moussa Hamadouche
Introduction: Postmenopausal osteoporosis may modulate bone response to wear debris. In this article, we evaluate the influence of oestrogen deficiency on experimental particle-induced osteolysis. Methods: Polyethylene (PE) particles were implanted onto the calvaria of normal controls, sham-ovariectomized (OVX), OVX mice and OVX mice supplemented with oestrogen (OVX+E). After 14 days, seven skulls per group were analyzed using a high-resolution micro-computed tomography (micro-CT) and histomorphometry, and for tartrate-specific alkaline phosphatase. Five calvariae per group were cultured for the assay of IL-1β, IL-6, TNF-α and receptor activator of the nuclear factor κB (RANKL) secretion using quantitative ELISA. Serum IL-6 concentrations were obtained. The expression of RANKL and osteoprotegerin (OPG) mRNA were evaluated using real-time PCR. Results: As assessed by μCT and by histomorphometry, PE particles induced extensive bone resorption and an intense inflammatory reaction in normal controls, sham-OVX and OVX+E mice, but not in the OVX mice group. In normal controls, sham-OVX and OVX+E mice, PE particles induced an increase in serum IL-6, in TNF-α and RANKL local concentrations, and resulted in a significant increase in RANKL/OPG messenger RNA (mRNA) ratio. Conversely, these parameters remained unchanged in OVX mice after PE implantation. Conclusions: Oestrogen privation in the osteolysis murine model ultimately attenuated osteolytic response to PE particles, suggesting a protective effect. This paradoxical phenomenon was associated with a down-regulation of pro-resorptive cytokines. It is hypothesized that excessive inflammatory response was controlled, illustrated by the absence of increase of serum IL-6 in OVX mice after PE implantation.